Compare · NVO vs TRDA
NVO vs TRDA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Entrada Therapeutics Inc. (TRDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TRDA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 781.3x TRDA ($250.8M).
- Over the past year, NVO is down 43.0% and TRDA is down 12.8% - TRDA leads by 30.2 points.
- TRDA has been more active in the news (9 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for TRDA).
- Company
- Novo Nordisk A/S
- Entrada Therapeutics Inc.
- Price
- $43.91+0.06%
- $6.54+1.47%
- Market cap
- $195.92B
- $250.8M
- 1M return
- -4.14%
- -4.18%
- 1Y return
- -43.00%
- -12.80%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Entrada Therapeutics Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TRDA
- SEC Form 4 filed by Director Parmar Kush
- SEC Form 4 filed by Director Kim Peter S
- SEC Form 4 filed by Director Chapman Gina
- SEC Form 4 filed by Director Radhakrishnan Maha
- SEC Form 4 filed by Director Thistle Mary
- SEC Form 4 filed by Director Zeiher Bernhardt G
- Entrada Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
- Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Zeiher Bernhardt G bought $29,316 worth of shares (5,000 units at $5.86) (SEC Form 4)